Healthcare

How did Celgene, AbbVie and Gilead fare last quarter?
Without strength in the big-cap leaders, this market is tough to trade.
Prices are extended on the downside.

Regeneron Shows Green Shoots Real Money Pro($)

Clues in the chart point to higher prices to come.
MCK has rolled over again and prices are pointed lower
Small caps are down 0.12% despite the strength in the Nasdaq ETF.
It looks like CAH will have a long road to recovery.
Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.

AbbVie Is Flexing Its Abs Real Money Pro($)

ABBV is now set up well for more upside.
Medtronic, Abbott Labs and Becton Dickinson appear to be offering buying opportunities.

Columnist Conversations

this stock is showing great relative strength today, superior volume and strong price action. BOUGHT ...
If we can answer that question above we will know when this market finally corrects. The Dippers showed up aga...
If GM goes ahead with borrowing an additional $3 billion to fund the pensions... 1)  They will be tran...
I see many people negative on Nasdaq and the FANG stocks today. I have written about these stocks quite often ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.